Investigational drug · Phase 3
Surufatinib
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Pancreatic Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
111
Any phase or sponsor naming "Surufatinib"
First trial start
2024
May 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Surufatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Surufatinib" as an intervention, largest first.
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerPivotal-lookingRecruiting
HutchmedIndustry
NCT06361888 · 502 participants (planned) · Start May 8, 2024 · Primary completion May 31, 2028
Drug: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine; Nab-paclitaxel Plus Gemcitabine and 1 more · For: Metastatic Pancreatic Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 52 sites in all
- Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort StudyActive, not recruiting
West China HospitalAcademic, hospital or other
NCT07534371 · 500 participants (planned) · Start Mar 6, 2026 · Primary completion Jul 2026
Drug: surufatinib; Somatostatin Analogs · For: Neuroendocrine Tumors
Sites: Chengdu, China
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07272512 · 350 participants (planned) · Start Nov 11, 2025 · Primary completion Nov 29, 2027
Drug: Surufatinib · For: Neuroendocrine Tumors; Neuroendocrine Neoplasms
Sites: Shanghai, China · 4 sites in all
- A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsPivotal-lookingStatus unknown
Hutchison Medipharma LimitedIndustry
NCT03873532 · 298 participants (planned) · Start Jul 10, 2018 · Primary completion Jun 2021
Drug: Surufatinib; Capecitabine · For: Biliary Tract Cancer
Sites: Beijing, China
Hutchison Medipharma LimitedIndustry
NCT04169672 · 248 participants · Start Dec 26, 2019 · Primary completion Feb 28, 2023
Drug: Surufatinib; Toripalimab · For: Advanced Solid Tumors
Sites: Beijing, China; Shanghai, China
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT02588170 · 219 participants · Start Dec 7, 2015 · Primary completion Mar 31, 2019
Drug: Surufatinib · For: Neuroendocrine Tumors
Sites: Beijing, China; Guangzhou, China; Chengdu, China · 5 sites in all
The First Hospital of Jilin UniversityAcademic, hospital or other
NCT07505472 · 212 participants (planned) · Start Feb 23, 2026 · Primary completion Dec 31, 2029
Drug: Experimental Group; Control group · For: Rectal Cancer
Sites: Changchun, China
- A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract CarcinomaStatus unknown
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT05064852 · 200 participants (planned) · Start Sep 20, 2021 · Primary completion Dec 20, 2022
Drug: Surufatinib · For: Biliary Tract Carcinoma
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsPivotal-lookingCompleted
Hutchison Medipharma LimitedIndustry
NCT02589821 · 195 participants (planned) · Start Dec 7, 2015 · Primary completion Nov 11, 2019
Drug: Surufatinib · For: Neuroendocrine Tumors
Sites: Beijing, China; Guangzhou, China; Chengdu, China · 5 sites in all
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaPivotal-lookingStatus unknown
Hutchison Medipharma LimitedIndustry
NCT05015621 · 194 participants (planned) · Start Sep 18, 2021 · Primary completion May 31, 2025
Drug: Surufatinib plus Toripalimab; 5-fluorouracil, Calcium folinate and Irinotecan · For: Advanced Neuroendocrine Carcinoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Randomized phase-II trial of surufatinib plus FOLFOX/FOLFIRI versus FOLFOXIRI as second-line therapy for metastatic colorectal cancer.
Su L, Lin P, Yin Y, et al. · Ann Med 2026
- Case Report: Apparent progressive complete mismatch repair protein loss during platinum-based chemotherapy in metastatic rectal neuroendocrine tumour grade 2.
Yang Y, Li G, Wang J, et al. · Front Oncol 2026
- A rare collision tumor of paraganglioma and intravascular large B-cell lymphoma: a case report and literature review.
Li Z, Ding J, Mu R, et al. · Am J Cancer Res 2026
- Clinical activity of chidamide-containing regimens after prior PD-1-based therapy in two patients with microsatellite-stable metastatic colorectal cancer: a case series and narrative review.
Chen R, Yang D, Xu H · Front Oncol 2026
- A Spatially Directed Microneedle Patch Enables Intratumoral Co-Delivery of FOLFIRINOX, Surufatinib, and Anti-PD-1 for Chemo-Immunotherapy of Pancreatic Ductal Adenocarcinoma.
Kong T, Xu X, Zhang X, et al. · Adv Sci (Weinh) 2026
- A Case Report of a Grade G2 Rectal Neuroendocrine Neoplasm with Perineural Invasion and Lymph Node Metastasis.
Menglan L, Yunyao L, Dong Z · Case Rep Oncol 2026
Also in development for Metastatic Pancreatic Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Olaptesed pegolNOX-A12Phase 22 trials
TME Pharma AG · Metastatic Pancreatic Cancer, Glioblastoma
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- HY-0102Phase 21 trial
Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer
- YL-13027Phase 21 trial
Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.